Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
about
Exciting new advances in neuro-oncology: the avenue to a cure for malignant gliomaDW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastomaDose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study.Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomideThe neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation.Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro dataRad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cellsPolish natural bee honeys are anti-proliferative and anti-metastatic agents in human glioblastoma multiforme U87MG cell lineNanostructured Pt(NH(3))(4)Cl(2)/SiO(2) for nanomedicine: catalytic degradation of DNA in cancer cellsEvaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.Temozolomide for treatment of brain metastases: A review of 21 clinical trials.Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.Comparable cell survival between high dose rate flattening filter free and conventional dose rate irradiation.Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain.Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.Antiproliferative effects of Tubi-bee propolis in glioblastoma cell lines.Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.CUX1 Stimulates APE1 Enzymatic Activity and Increases the Resistance of Glioblastoma Cells to the Mono-Alkylating Agent, Temozolomide.Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.Short delay in initiation of radiotherapy for patients with glioblastoma- effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group (RTOG) database.Anti-tumour effects by a trimodal combination of temozolomide, meloxicam and X-rays in cultures of human glioma cells.
P2860
Q24632791-4B36FC69-D18A-403E-8D67-2993C89FD09CQ28730443-AB5E89B6-E281-4D55-A8BF-D7BE12304AE6Q33386298-CFF84500-6A42-41DA-A43E-F2C855C45D13Q33409478-D8158C87-0B38-459B-8D80-CBAECD440146Q33429765-3EBDFD7E-A4AD-4227-B052-9966C68E9E62Q33655371-75EC26E8-A3B5-4335-8F3A-32BE909D3AA5Q34000287-7F673C18-5C0D-45A9-B0FA-39AB1CCEB5D1Q34013084-6EA71796-8A42-447F-A9E4-61065BB0247CQ34134930-04FDB32D-95AC-43BA-A40D-550CACF09D67Q34977354-31048075-C74D-49D7-B82D-8729A84A4DC3Q35110867-C1F9F3BD-160A-4F02-8DE6-9C552EBBE2B4Q35547337-7F75DD3D-CF6F-4E49-818D-8B4C9C4AACA7Q36755432-921AFF39-9C68-407B-B69B-335B5439334DQ37412251-39351DC1-DAD5-4DCB-AC98-86D102674E41Q37576025-D846E363-C334-42B2-BDEE-342072F2699CQ37766550-865F1529-A81E-43FF-A783-01B14AD98FCEQ39249483-C06E2611-79C2-413F-A2C8-5341BDC3591EQ39524840-3E11F634-5AC0-4498-B27B-93E490F70623Q39670061-B0849945-04B2-4E80-B789-E4559A057077Q39820294-3902AC27-8BEB-463F-A883-2E310622325CQ39967654-14733DCE-2A2A-4B6C-BA0D-EA1999FE0540Q40538138-82F8EE0E-0067-40EF-BB0D-F55EEA9B328AQ41634276-CBDDBE36-F609-4B17-823B-D16DDE8FC4F9Q42170315-76FD0095-5671-4D74-87E3-E9639C6AFB0CQ43257040-FAC438B4-5AEC-40C8-BAB4-F863F9FDACABQ45158949-087F2C22-88DD-425E-816D-5391CD59373FQ46146247-7D2A6DFB-554A-4F57-A01C-B8A150BF9E52Q46876827-79C2FFEB-51F8-4A86-9211-950D49CE8025Q47647202-42F4874F-255B-467F-8938-34335CEE4E85Q48181947-E3E4630C-86CA-436C-BC79-D5C53F513124Q50026495-B37E9D5C-1C6A-4D37-9194-28E4DD52EC6FQ55463690-C872977F-F836-4C20-9031-4F8A93D456E8
P2860
Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Differential radiosensitizing ...... lastoma multiforme cell lines.
@en
type
label
Differential radiosensitizing ...... lastoma multiforme cell lines.
@en
prefLabel
Differential radiosensitizing ...... lastoma multiforme cell lines.
@en
P2093
P1476
Differential radiosensitizing ...... blastoma multiforme cell lines
@en
P2093
Jaap van den Berg
Krista A van Nifterik
Lukas J A Stalpers
M Vincent M Lafleur
Peter Sminia
Sieger Leenstra
Theo J M Hulsebos
P304
P356
10.1016/J.IJROBP.2007.07.2366
P407
P577
2007-11-01T00:00:00Z